Login / Signup

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.

Jing HuangJuxiang XiaoWentao FangPing LuQingxia FanYongqian ShuJifeng FengShu ZhangYi BaYang ZhaoYing LiuChunmei BaiYuxian BaiYong TangYan SongJie He
Published in: Cancer medicine (2021)
Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102), NCT02649361.
Keyphrases
  • squamous cell carcinoma
  • small cell lung cancer
  • open label
  • double blind
  • placebo controlled
  • randomized controlled trial
  • study protocol